Open AccessUse of Biosimilars in Pediatric Inflammatory Bowel Disease
Author(s) -
Ridder Lissy,
Assa Amit,
Bronsky Jiri,
Romano Claudio,
Russell Richard K.,
Afzal Nadeem A.,
Hauer Almuthe C.,
Knafelz Daniela,
Lionetti Paolo,
Strisciuglio Caterina,
Veres Gábor,
Winter Harland,
Wolters Victorien M.,
Sladek Malgorzata,
Vulto Arnold G.,
Dias Jorge A.
Publication year - 2019
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002141
Subject(s) - biosimilar , medicine , inflammatory bowel disease , infliximab , position statement , position paper , intensive care medicine , disease , pediatrics , family medicine , pathology
Biologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.